MedTrace Logo

Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports

NCT04309240 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 204

Last updated 2020-03-16

No results posted yet for this study

Summary

Rivaroxaban has been developed in the various clinical settings.Although cancer-associated DVT or PE was included in previously programs, limited patients of the total populations were cancer patients with totally implantable access ports in these studies. In this sense, investigators feel that new oral anticoagulants should be re-investigated in this highly specific patients group.Therefore, investigators are planning to conduct a prospective study to estimate the efficacy and safety of rivaroxaban for thromboprophylaxis in high-risk cancer patients with totally implantable access ports.

Conditions

  • Rivaroxaban
  • Thromboprophylaxis
  • Cancer

Interventions

DRUG

Rivaroxaban

Rivaroxaban 10mg orally per day for 90days

Sponsors & Collaborators

  • LiuZhou People's Hospital

    lead OTHER

Principal Investigators

  • yu bin, PHD · LiuZhou People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-08
Primary Completion
2022-03-08
Completion
2022-03-08

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04309240 on ClinicalTrials.gov